Sector News

Hikma to split U.S. business; CEO Raya to depart

June 26, 2017
Life sciences

Hikma Pharmaceuticals PLC said Monday the chief executive of the U.S. business Michael Raya is retiring after 25 years on the job amid organizational changes at the division.

From July 1, the U.S. business will be organized into two entities–U.S. Generics Division and U.S. Injectables Division–both of which will report to the chairman and the chief executive officer of Hikma, the company said.

The company said it is doing do because it wants to “reflect its enhanced U.S. market positioning and to better align with the global Hikma organization.”

By Olga Cotaga

Source: Market Watch

comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach